Study design: Pooled data of 1557 patients treated with stents in three randomized controlled trials (RCTs; EVA-3S, SPACE, ICSS) comparing carotid artery stenting (CAS) vs carotid endarterectomy (CEA) for symptomatic disease.
Good results of thoracic endovascular aortic repair even by low-volume surgeons
Key findings: The query identified 1838 patients who underwent thoracic endovascular aortic repair (TEVAR) for aortic dissection (n ¼ 334), nonruptured aneurysm (n ¼ 1278), and ruptured aneurysms (n ¼ 226). TEVAR implantation significantly increased over the 10 years in all groups with a recent increase for dissection. Between 2005 and 2007, patients were more likely to be treated at high-volume facilities (>17 per year) and by high-volume surgeons (>5 per year), but since 2011, about half of the patients underwent TEVAR by low-volume surgeons (<3 per year). Neither surgeon nor hospital volume were associated with clinical outcome.
Conclusion: Comparable results were obtained with TEVAR across hospital and surgeon volume strata. These findings have implications for credentialing and regionalization of TEVARs and other vascular procedures.
Commentary: Let's face it -performing an electiveTEVAR for a mid-descending thoracic aortic aneurysm is technically as easy, or easier, than performing an elective EVAR in most cases. If a medical center has anesthesiologists trained to perform spinal catheter drainage, suitable intensive care unit facilities, and other necessary adjuncts to perform "easy" TEVARs, why not allow low-volume surgeons to perform them at low-volume hospitals? Well, no one would argue that someone doing something in high volumes at a place where a lot of procedures are done will get better results than someone doing a few procedures at a low-volume facility. Would any of us go to a car mechanic who fixes engines less than five times a year at a garage where all of the mechanics at that garage do less than 17 repairs a year? I assume the authors of this article would agree that using this same data source over a longer period of time, reporting a larger series of patients might show that results of elective TEVARs might be better at high-volume hospitals when performed by high-volume surgeons. Along the same lines, the Society for Vascular Surgery Clinical Practice Guidelines for abdominal aortic aneurysms recommends that EVARs and open AAA surgery should be performed at centers that perform more than 10 of each of these procedures annually with acceptable complication rates. But, if we accept that a low-volume surgeon will refer TEVARs to high-volume hospitals or surgeons when the referring surgeon does not feel comfortable doing complex procedures, and if the low-volume surgeon analyzes his or her results with suitable databases such as the VQI, should regionalization be mandated or even recommended? This question has far-reaching implications, and I struggle with the concept of regionalization from both sides of the discussion. We have to realize that most surgeons in the country can find another hospital and another surgeon who does more of a certain procedure than they do, so when would they ever do a case? Would low-volume surgeons be willing to take a hit to their paycheck on a regular basis for the sake of regionalization? The reality is that regionalization may already be happening due to natural selection. Establishment of Vascular Centers that meet high-level criteria may drive regionalization even further simply by increasing public awareness. The problem is that hospital credentialing committees are the ultimate power-brokers who determine who is allowed to perform certain procedures. If vascular surgery becomes regionalized, and vascular surgeons tell their hospital administrators they no longer perform certain procedures, and those patients then are referred to high-volume hospitals, will cardiologists take up the slack and perform TEVARs, EVARs, and carotid stenting at that hospital if they are allowed to do so? My crystal ball does not provide the answer (but I can make a guess).
Incidence of carotid artery stenosis after radiation
The Key findings: Risk of carotid stenosis (>50%) in 366 HNC patients was 34% 8 years after RT. Multivariate analysis showed that diabetes was predictive of time to carotid artery stenosis but not RT dose.
Conclusion: The high incidence of carotid artery stenosis after RT warrants carotid artery screening after RT in HNC patients. Although stenosis was not related to RT dose, the limited mean follow-up of 4 years in this series may be too short to detect a dose response effect.
Commentary: Current carotid artery screening recommendations do not include patients who had RT for HNC. However, head and neck RT has been shown to be an independent risk factor for asymptomatic carotid artery stenosis, ranging from as low as 12% at 6 years to as high as 20% at 2 years. In this series, the chance of developing >50% asymptomatic carotid stenosis after RT was 34% at 8 years. The Society of Vascular Surgery recommends carotid artery screening when carotid artery stenosis prevalence is more than 20%. But, what is the natural history of carotid artery stenosis due to RT? Is the incidence of stroke higher, lower, or the same compared to atherosclerosis? For carotid artery stenosis due to atherosclerosis, most vascular surgeons recommend prophylactic carotid endarterectomy for stenosis >70%-80% in good-risk patients. Should HNC patients be considered "good risk"? If their long-term survival is good, then treatment would seem reasonable. Some radiated necks are not too badly scarred and surgery can be considered, but experienced vascular surgeons who have operated on these patients are delighted that carotid artery stenting (CAS) is another alternative. The real question is whether CAS to treat asymptomatic 80%-99% carotid stenosis after RT is better than antiplatelet agents alone. The Centers for Medicare and Medicaid Services (CMS) appears to agree that these asymptomatic patients with history of head and neck RT will do better if CAS is performed, but only when a flow-reversal protection technique such as TCAR is used (and the interventionalist participates in the Vascular Quality Initiative [VQI]). CMS does not reimburse interventionalists for asymptomatic carotid disease when a distal protection device is used unless the patient is in CREST2.
Duplex ultrasound should be the preferred surveillance tool for endovascular aortic aneurysm repair
The Role of Duplex Ultrasound in Detecting Graft Thrombosis and Endoleak After Endovascular Aortic Repair for Abdominal Aneurysm Key findings: A total of 905 patients were followed for a mean of 5.5 years with computed tomography angiography (CTA) and DU performed annually within 1 month of each other. The accuracy of DU to detect endoleak was 97%. Mean diameter difference of the aortic sac was 2.5 mm between the two studies.
Conclusion: DU was a reliable exam in identifying the vast majority of endoleaks and all graft thrombosis after EVAR compared to CTA, with slight underestimation of sac diameter.
Commentary: The Society for Vascular Surgery Clinical Practice Guidelines for abdominal aortic aneurysms recommends that CTA or duplex ultrasonography be performed annually as surveillance of EVARs after the first postoperative CTA. Many vascular surgical groups, including ours, began performing DU as the sole surveillance study about 15 years ago and do not obtain a CTA unless DU suggests an endoleak, sac growth >5 mm or a failing limb. Decreased costs, patient convenience, and elimination of radiation risk are well-known advantages of using DU as the surveillance tool. Obese patients and difficult anatomy can make DU surveillance difficult or impossible, but the vast majority of EVARs can be followed using DU with minimal risk of missing significant sac enlargement, endoleaks, or limb stenosis. For those considering adopting this strategy, I recommend doing what these authors did e obtain both CTA and DU within 1 month of each other for a couple of years and compare the results. I cannot fathom why more vascular surgeons do not use DU as the primary or sole surveillance study for EVARs other than not having expert vascular technologists in their noninvasive vascular laboratory.
